A new scoring system identifies risk factors for disease recurrence after stem cell transplantation in leukemia patients, ...

In 2023, semaglutide emerged as the top-selling drug in the USA, generating $13.8 billion in sales. Read more.

Discover a study that shows that modulating STAT6 directly may represent an innovative strategy for managing severe, ...

Phase 3 psoriasis trial results highlight the efficacy and safety of icotrokinra, an oral IL-23 therapy showing promise for ...

New research reveals rare aneuploid cells in healthy breast tissues, showing cancer-like mutations that increase with age, ...

This new research sheds light on shared and subtype-specific genetic variations and points to potential targets ...

Pfizer's anti-tissue factor pathway inhibitor has been approved for the treatment of haemophilia A & B by the European Commission.

Phase 1 trial demonstrates safety and effectiveness of neoantigen DNA vaccines in triple-negative breast cancer, achieving 87.5% recurrence-free survival at 36 months.

Discover how kidney function decline in ATTR-CM patients predicts higher mortality, highlighting its role as a critical marker in disease management and care optimisation.

Discover how combining brain stimulation therapies improves depression treatment outcomes compared to single therapies, ...

Discover how ultrasound renal denervation offers long-term blood pressure control and reduces medication needs in resistant ...

The novel IL-17A and IL-17F inhibitor has been approved for moderate to severe hidradenitis suppurativa, a chronic and ...